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Abstract
Introduction: Burkitt’s lymphoma (BL) is a virus associated childhood B-cell cancer common in Eastern Africa. Continued 
survival of  B-cells in germinal centres depend on expression of  high affinity immunoglobulins (Ig) to complementary antigens 
by somatic hypermutation of  Ig genes. Cellular microRNAs, non-coding RNAs have been reported to play role in cell cycle 
regulation. Both viral antigen dependent mutation and micro-RNA expression maybe involved in BL pathogenesis.
Objective: To describe immunoglobulin heavy variable (IgHV) rearrangement and micro-RNA expressions in BL tumours.
Methods: Genomic DNA were extracted and purified from BL tissue blocks at Moi Teaching and Referral Hospital, before 
amplification using IgHV consensus primers and sequencing. The sequences were then aligned with germline alleles in IMGT/
V-QUEST® database. Total RNA extracted from tissue blocks and cell lines were used to determine relative expression of  hsa-
miR-34a and hsa-miR-127.
Results: In all tumours, allele alignment scores and number of  mutations range were 89.2-93.2%, 15-24 respectively. The range 
of  IgHV amino acid changes were higher in EBER-1+ (15-25) than EBER-1- (9-15). In MYC+ tumours, the relative expression 
were: hsa-miR-127(2.09);hsa-miR-34a (2.8) and MYC- hsa-miR-127 (1.2), hsa-miR-34a (1.0).
Conclusion: B-cell in BL contained somatic mutated IgHV gene and upregulated cellular microRNAs with possible pathoge-
netic role(s).
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Introduction 
Burkitt’s lymphoma (BL) is common  aggressive child-
hood non-Hodgkin lymphoma (NHL) endemic in 
sub-Saharan Africa (Orem, Katongole, Lambert, de San-
jose, & Weiderpass, 2007). In this region, non-random 
and spatial-temporal clustering of  BL appear to suggest 
relationship with prevalent infection with P. falciparum, 
Epstein Barr virus (EBV), Kaposi sarcoma-associated 
herpesvirus (KSHV), Human herpesvirus 8 (HHV-8) 
and Human immunodeficiency virus (HIV) (Rainey et 
al., 2006; Thapa, Li, Jamieson, & Martínez-Maza, 2011). 
Persistent exposure to these pathogens thought to play  a 
role in endemic BL pathogenesis (Mutalima et al., 2008).
Normally B cells home in germinal centres (GC) where 
survival depend on their  expression of  high affinity im-
munoglobulin B-cell receptors (BCR) capable of  recog-
nising corresponding pathogen antigens. High-affinity 
receptor rearrangements are achieved through somat-
ic hypermutation. A  process in which germinal centre 
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B-cells acquire mutations at a high rate within the immu-
noglobulin complementarily-determining regions (CDR) 
including IgHV (Hecht & Aster, 2000). Because somatic 
hypermutation is largely confined to germinal centre, its 
features therefore marks a B cell as being of  GC or post 
GC origin. This apparent obvious GC derivation of  many 
Burkitt’s lymphoma  contradicts the fact that some BL 
tumours growths are extra nodal and involve tissues that 
do not normally contain germinal centres under physio-
logical condition (Cogliatti et al., 2006). The precise nor-
mal cell counterpart of  B-cells in Burkitt’s lymphoma is 
therefore unclear and controversial. The impact of  infec-
tions such as EBV and posttranscription regulators such 
as microRNAs on B-cell differentiation has been intense 
discussion but remains largely unclear. It is known that 
lymphoid neoplasms in many respects recapitulate nor-
mal stages of  lymphoid cell differentiation, activation, 
maturation and function (Jaffe, Harris, Stein, & Isaacson, 
2008), a fact useful  for their classification and diagnosis.
MicroRNAs (miRNAs) are small endogenous non-cod-
ing RNAs approximately 21–23 nucleotides, long found 
in host and pathogens. Cellular miRNAs constitute ap-
proximately 1–3% of  human genome of  which about 
940 have been identified (Sandhu, Croce, & Garzon, 
2011). MicroRNAs are critical gene regulators. They con-
trol about 30% of  human genes by mediating cleavage 
and/or inhibition of  genomic translation by binding to 
3’ untranslating region (UTR) of  their target messenger 
RNAs (mRNA). Many miicroRNAs have been reported 
to influence cell growth, development and differentiation, 
making their dysregulation likely to  result in malignan-
cies including Burkitt’s lymphoma (Esquela-Kerscher & 
Slack, 2006). Due to their non-immunogenic property of  
microRNAs, viral miRNAs are used to execute viral la-
tency to avoid immune response to viral antigens by the 
host (Lin & Flemington, 2011).
Systematic profiling of  microRNAs in lymphoma patient 
samples suggests a role in lymphomagenesis (Anna On-
nis et al., 2010). Expression patterns of  some microR-
NAs can provide insight into BL molecular phenotype 
and pathogenesis (Zhang et al., 2009), making them 
promising tools to explore the molecular signature of  
BL and other cancers (Lenze et al., 2011). Putting IgHV 
mutation and miRNA expression profiles together, may 
help to better describe and differentiate BL from other 
B cell lymphomas. We investigated B cell phenotype in 
selected BL tumours in terms of  immunoglobueavy vari-
able (IgHV) genes mutation and microRNA expression 
at Moi Teaching and Referral Hospital (MTRH) in west-
ern Kenya.
Materials and methods
A cross sectional study of  children and adolescents 
aged ≤18 years presenting with jaw or abdominal mass-
es was carried out at Moi Teaching and Referral Hospi-
tal (MTRH) in western Kenya between 2012 and 2013. 
Initially, tissue sections were evaluated by histology and 
a panel of  immunohistochemistry antibodies including 
EBER-1 and MYC. Demographic and clinical informa-
tion were obtained from structured questionnaire and 
hospital files. Parental informed consent was obtained 
from each participant before recruitment. Patient infor-
mation and specimen handling and processing were done 
in strict confidence. Institutional Research and Ethics 
Committee (IREC) of  Moi University/MTRH approved 
the study, FAN 000654.
Genomic DNA extraction and sequencing was done on 
previously diagnosed BL cases using histology, immu-
nohistochemistry and fluorescent in-situ hybridisation 
(FISH).  The DNA was extracted from 20-μm–thick 
sections of  formalin fixed paraffin embedded (FFPE) 
tissue blocks, by BioRobot EZ1 (Qiagen, Milan, Italy), 
following the manufacturer’s protocol. Only extracts 
with DNA concentration ≥300 ng/µl were considered 
to contain sufficiently intact DNA for amplification and 
analysis for IGHV-IGHD-IGHJ rearrangement or so-
matic hypermutation. To avoid cross-contamination, all 
procedures performed before PCR amplification such as 
cutting of  tissue sections and proteinase K digestion were 
performed in designated pre-amplification, amplification 
and post amplification sections of  the laboratory. Poly-
merase chain reaction (PCR) amplifications were done on 
genomic DNA extracts using consensus primers for the 
IGHV framework region 1 (FR1), along with consensus 
J segment primers (BIOMED-2 Protocol) and multiplex 
identifier (MID) at each 5’ end the primers to barcode the 
sample. Amplification efficiencies ranged from 50-100%. 
The PCR amplification products were directly sequenced 
using ABI PRISM® BigDye Terminator v1.1 Ready Re-
action Cycle Sequencing kit and ABI PRISM 310 Genetic 
Analyzer (both from Applied Biosystems, Germany). The 
resulting sequences were then analysed on ImMunoGe-
neTics® (IMGT) database using IMGT/V-QUEST tool 
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(version 3.3.5). This tool determines and localizes somat-
ic mutations in immunoglobulin rearranged sequences by 
aligning with the database alleles.
MicroRNA extraction and expression
Total RNAs were extracted from about four (4) pieces of  
5μm thick FFPE tissue sections each using miRNeasy® 
FFPE kit (Qiagen) following the manufacturer’s instruc-
tions. Briefly, the tissue sections were deparaffinised, di-
gested in proteinase K, then heated on a Thermoblock at 
80oC for 15 minutes followed by DNase treatment and 
binding to RNeasy MinElute® column, from where total 
RNA including microRNA were then eluted in a mini-
mum quantity of  4μl RNase-free water. The amount and 
purity of  RNA extracted were evaluated by measuring ra-
tio of  absorbance at 260nm and 230 nm using Thermo 
Scientific Nanodrop® spectrophotometer (ND-1000, 
Nanodrop, Thermo Scientific®).  A ratio of  approxi-
mately 2.0 was considered as pure total RNA.  A lower ra-
tio indicates protein contaminants. Expression of  cellular 
miRNA levels were then evaluated using real-time quan-
titative reverse transcription (qRT-PCR) using TaqMan® 
MicroRNA Assay kit according to the manufacturer’s in-
structions. Specific cDNA were prepared using specific 
TaqMan® primers for hsa-miR-34a, hsa-miR-127 and 
RNU-43 (#4366596 Applied Biosystems, Germany) by 
means of  reverse transcription kit. The expression levels 
of  miRNAs were normalized to that of  RNU43, which 
was stably expressed among the samples. Controls were 
prepared from paraffin-embedded blocks made from Cag 
(EBV-positive) and Ramos (EBV-negative) cell lines. The 
data generated were analysed using proprietary software 
DataAssist® to derive relative quantity of  miRNA ex-
pression.
Data management
The study data were entered into computer for storage 
and initial analysis. Descriptive analyses were performed 
by using frequency tables, for categorical variables using 
R Studio version 1.1. For continuous variables such as 
age, means and other relevant measures of  central ten-
dency were used.
Results 
There were a total of  thirty three children and adoles-
cents with Blin this series and consisted of  78.8%, 21.8% 
males and females respectively. Of  the randomly selected 
four BL cases, there were 3 males and 1 female aged be-
tween 4 and12 years, tumour site; 3 jaw, 1 abdominal  with 
variable EBER-1 and MYC status (Table 1). 
Table 1. Case gender, age tumour site and EBER-1 status 
 
Case Sex Age , y Tumour  site EBER-1 
1 female 4 Jaw Positive 
2 Male 7 Abdominal Positive 
3 Male 6 Jaw Positive 
4 Male 12 jaw Negative 
  
Cases 1-3 were positive for EBER-1 while case 4 was 
negative for EBER-1 (Table 2). After aligning DNA am-
plicons sequences with the closest V-regions alleles from 
the IMGT/V-QUEST reference database, percentage nu-
cleotide identity were: case1 (89.2%) case2 (93.2%), case3 
(90.4%), case4 (89.2%) (Figures 1 & Table 2).  
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                 Figure 1. CDR alignment with corresponding alleles. Dashes indicate identical nucleotides.  
                 Dots indicate gaps or nucleotides not taken into account for the alignments.  Nucleotide  
                 identity (%) cases1=90.5, case2= 93.2, case3= 90.4, case4= 89.2. 
Table 2. IgHV gene and closest germline allele’s usage (%), V region mutations 
 
Case Allele V-gene & allele 
Identity (%) 
V-region 
mutations 
Amino 
acid changes 
CDR-IMGT 
lengths 
EBER+/- 
1 HomsapIgHV4-34*01 F 90.5 22 14   
8.7.14 
Positive 
2 HomsapIgHV1-18*01 F 93.2 15 9   
8.8.15 
Positive 
3 HomsapIgHV-13*01 F 90.4 22 13   
8.7.20 
Positive 
4 HomsapIgHV3-21*01 F 89.2 25 14   
8.8.15 
Negative 
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The number of  mutation (amino acid changes) in the 
V-region fromFR1 toFR3 compared to the closest germ-
line V-genes of  similar IMGT/CDR lengths were: case1; 
22(14), case2; 15(9), case3; 22(13) and case4; 25(14) re-
gardless of  EBER-1 status (Table 2). Relative expression 
of  cellular microRNAs, hsa-miR-127 and hsa-miR-34a 
were higher (2.8 vs 2.09) in MYC-positive BL compared 
to MYC-negative BL cases, Ramos (EBER-1-negative) 
and Cag (EBER-1 positive), a multiple myeloma cell lines 
(Figure 2).
      
a)                                                                                              b) 
 
 
c) 
 
Figure 2. Relative expression of; a) hsa-miR-127 in BL cases, b) hsa-miR-127, in Ramos and Cag cell lines and  
c) hsa-miR-34a 
Discussion 
In this study, IgHV DNA input sequences of  Burkitt’s 
lymphoma BCRs harbour mutations compared to their 
corresponding germline alleles in IMGT/V QUEST da-
tabase suggesting presence of  somatic mutations possi-
bly due to interactions with an extrinsic pathogen anti-
gen in the germinal centres. This may imply that these B 
cells in the studied tumours are antigen experienced and 
therefore supports GC phenotype of  BL tumours cells 
as previously reported (God & Haque, 2010). Amato et 
al (2016) also reported a higher mutation frequency in 
EBV associated BL compared to sporadic BL, support-
ing view that antigen selection pressure may be playing 
a role in the pathogenetic pathway of  endemic BL. In 
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this current study, both EBER-1 positive and negative 
tumours showed evidence of  V-gene mutation in IgHV 
BCR. The fact that EBV encoded products detected in 
these tumours is consistent with Navari et al (2018) that 
Epstein-Bar virus encoded  RNA may contribute patho-
gentic effects by interfering with diverse  cellular mech-
anisms including immunosurveillance, cell proliferation 
and apoptosis. On the other hand, some studies have 
reported BL with undetected EBV encoded products 
(Leucci et al.,2010). The absence of  EBER-1 in some 
but not all BL tumours may mean that   in some BL, 
the malignant B cells have different maturation stage(s) 
compared to their EBER-1 positive counterparts. It is 
noteworthy that all the BL tumours in this study stained 
positive staining for CD20 and CD10 (results not shown), 
which are known are markers associated with centroblast 
and germinal centre (GC) B cells respectively. But this 
apparent GC derivation contrasts a frequent observation 
that some BL tumour growths are extra nodal and do not 
involve tissues that contain germinal centres under phys-
iological conditions. Thus the IgHV mutations observed 
in these tumours, in addition to CD10 and CD20 pheno-
type appear to suggest that B cells in the studied tumours 
are most likely derived from centroblast, germinal centre 
or post-germinal centre and are antigen experienced. This 
supports findings by Tamaru et al (1995) that BL cells are 
characterised by  antigen driven  somatic hypermutated 
IgVH genes . Thus, neoplastic B cells in BL appear to 
arise either from early centroblasts or GC stages that are 
arrested after somatic hypermutation. Germinal centre 
phenotype and/or MYC expression in some BL tumours, 
suggest probable errors in class-switch recombination 
stage Piccaluga et al (2011). The differences in  cells of  
origin of  BL tumours supports the view that there are 
different pathologic mechanisms or entities of  BL (Bellan 
et al., 2003)
This study reports, increased relative expressions of  hsa-
miR-34 and hsa-miR-127 in c-myc and EBV positive BL 
compared to Ramos cell line,  an EBV-negative BL de-
rived cell lineThis evidence supports of  those by Leucci 
et al (2008) that viral encoded products c myc expression 
and host miroRNA pattern.. Studies by Onnis et al (2012) 
also reported that EBV encorded nuclear antigen-1 in-
duce host hsa miR- 127 which acts post transcriptionally 
to dysregulate memory B cells, leading to BL pathogene-
sis . The high expression of  hsa-miR-34a by c myc pos-
itive cell lines further suggests a networking relationship 
between pathogen antigen, viral and host microRNAs. 
Blockade of  B cell differentiation by increased hsa miR-
34a expression has been proposed (Lisio et al., 2012). The 
role of  EBV and/or microRNAs lymphoma pathogene-
sis is evident.
Conclusion
B cells in Burkitt’s lymphoma tumour studied here con-
tained rearranged Immunoglobulin heavy variable (IgHV) 
region genes, antigen driven somatic hypermutations with 
of  CD10 and CD20 phenotype, suggesting either GC or 
post GC derivation. Higher relative expressions of  cellu-
lar microRNAs hsa-miR 34a and hsa-miR 127 in EBER-1 
and MYC+ positive BL tumours further implicate miR-
NAs and pathogen antigens in lymphomagenesis, and 
can provide potential therapeutic applications.  Profiling 
other microRNAs and mutation in larger BL series is rec-
ommended.
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